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Abstract
Breast cancer is the most common form of cancer afflicting women in the United States;
one out of eight women will be diagnosed with breast cancer during her lifetime. Currently,
screening is performed by a combination of annual clinical breast examinations and x-ray
mammography. However, only 10 to 25 percent of suspicious lesions detected during
mammography are diagnosed as malignant upon biopsy, which implies that a large number
of biopsies can be avoided. Although mammography images anatomic changes, it is not
sensitive to the underlying morphological and biochemical changes that distinguish benign
and malignant breast lesions. Presently employed diagnostic procedures are invasive, time
consuming, and expensive. Thus, there is a clinical need to develop new tools for the early
diagnosis of malignancy in the breast.
In recent years our laboratory has explored the use of Raman spectroscopy for diagnosing
disease; one important area is the detection of breast cancer. Raman spectroscopy provides
information about the morphological and biochemical make up of tissue and, with the aid of
our diagnostic algorithm, has provided good results in distinguishing between malignant
and benign breast lesions, with a sensitivity, specificity, and an overall accuracy of 90, 96,
and 86 percent, respectively [Haka,2004]. Although these initial results are promising, we
would like to improve the overall accuracy. Another promising spectroscopic technique
developed in our laboratory is tri-modal spectroscopy (TMS), the combination of diffuse
reflectance (DRS), intrinsic fluorescence (IFS), and light scattering spectroscopy (LSS).
This technique has been successfully applied to the diagnosis of epithelial neoplastic tissue,
leading to the interest in exploring its application to the diagnosis of lesions in breast tissue.
Finally, the Raman and DRS/IFS modalities provide complementary information and the
combination of this information into a single diagnostic algorithm may provide superior
diagnostic capabilities.
The central theme of this research is to investigate DRS/IFS as a useful technique for the
diagnosis of breast cancer and to evaluate the effectiveness of its combination with Raman
spectroscopy. Through this research, we hope to aid the medical community in early
diagnosis, treatment, and prevention of breast cancer.
Thesis Supervisor: Michael S. Feld
Title: Professor of Physics
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Chapter 1. Introduction
1.1 Introduction and Motivation
Breast cancer is one of the most common forms of cancer to afflict women in the United
States. One out of every eight women will be diagnosed with breast cancer during her
lifetime. The mortality rate due to breast cancer is second only to lung cancer. Nearly
forty thousand women died in 2003 from this disease [Jemal,2004] and the survival rate
critically depends on early diagnosis.
Mammography is currently the leading diagnostic technique used for the detection of
non-palpable, highly curable breast cancer [Dahnert,1999]. It relies on finding density
changes in the breast tissue. However, because these changes do not uniquely correlate
with breast cancer, abnormalities identified with mammography must be further
investigated with biopsy. Thus, mammography is used only as a screening technique, not
as a diagnostic one. Only 10 to 25 percent of suspicious lesions found during
mammography are diagnosed as malignant upon biopsy [NCI,2004]. Currently employed
diagnostic procedures are invasive, time consuming and expensive, and this has
motivated scientists to investigate new tools for the early diagnosis of malignancy in
breast tissue.
1.2 Minimally-Invasive Techniques and Previous Work
Optical techniques offer a means to gain morphological and biochemical information of
tissue in a non-destructive manner, since optical radiation is non-ionizing. Furthermore,
light delivery and collection is performed with minimal invasion via optical fibers.
Optical instrumentation is generally inexpensive, portable, and compact, making it
adaptable to a clinical setting. Presently, a variety of optical imaging and spectroscopic
techniques are being explored with the aim of improving breast cancer diagnosis, with an
emphasis on improving the ability to discern benign from malignant lesions. The
techniques, employing visible or near-infrared light, have the potential to provide
chemical information and assist pathologists in diagnosing cancer.
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Diffuse optical tomography (DOT), an optical analogue of X-ray, studies the propagation
of amplitude-modulated pulses of light through the breast, is non-invasive and can detect
lesions deep (10 cm) within the tissue. DOT employs diffuse light that propagate through
tissue; it provides three-dimensional tomographic images of the internal organs. Some
diagnostic ability has been demonstrated based on the detection of oxy/deoxy
hemoglobin with a contrast agent [Ntziachristos,2001]. However, DOT can only detect a
limited number of chemicals and its low resolution results in small lesions going
undetected.
Unlike DOT, optical spectroscopic techniques sample the tissue locally with a volume
less than 1 mm 3 . Light delivery and collection are accomplished by means of optical
fibers that can be incorporated into a biopsy needle. Depth information can be extracted
as the needle is inserted or withdrawn. In contrast to a standard biopsy, a spectroscopic
transdermal needle measurement has the advantage of providing immediate diagnosis. As
a result, spectroscopy has the potential to reduce both the likelihood of a non-diagnostic
biopsy, which requires a repeat of needle or surgical biopsies, and patient anxiety by
eliminating the currently unavoidable wait for a traditional histopathology diagnosis.
Previously to our own work, several groups have investigated Raman spectroscopy for
diagnosing cancer. The first Raman spectroscopy experiment of breast tissue was
performed in 1991 [Alfano,1991]. Redd et al. soon followed and examined the
application of Raman spectroscopy using visible excitation [Redd,1993]. In our
laboratory, Raman spectroscopy has been investigated as a diagnostic modality for breast
cancer for nearly 15 years. Our approach has been centered on accurately modeling
spectra with a set of morphological basis spectra and achieving diagnostic algorithms that
have physical interpretation valuable to pathologists. Results from an ex vivo study
conducted at the University Hospital in Cleveland confirmed that Raman spectroscopy is
able to distinguishing benign and malignant lesions, with a sensitivity and specificity of
90 and 96 percent, respectively, and an overall accuracy of 86 percent [Haka,2002].
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Raman spectroscopy has been successful in distinguishing cancerous from non-cancerous
lesions. However, the model and algorithm misdiagnose some benign tumors, such as
fibroadenoma. Our laboratory has also been successfully exploring the use of trimodal
spectroscopy (TMS: diffuse reflectance, light scattering and intrinsic fluorescence
spectroscopies) for the diagnosis of epithelial lesions, with excellent success. In a
parallel study, I have used fluorescence and reflectance spectroscopies to detect its
feasibility and efficacy for the diagnosis of breast cancer.
A few researchers have used diffuse reflectance spectroscopy [Bigio,2000, Yang,1997]
fluorescence spectroscopy [Alfano,1987, Nair,2002, Shama,1996] to study breast tissue.
They have achieved some success. Gupta and Majumder et al. [Gupta, 1997, Majumder,
1998] analyzed different data sets collected from the same set of breast tissues ex vivo
and showed that the emission spectra at excitation wavelengths of 340 and 488 nm and
excitation spectra at emission wavelengths 390 and 460 nm exhibit significant differences
between normal, benign and malignant tissues. Palmer et al. [Palmer,2003] also
examined fluorescence and diffuse reflectance spectroscopies. The results from this study
are promising: multiexcitation fluorescence spectroscopy is successful in discriminating
malignant and nonmalignant tissues, with a sensitivity and specificity of 70 and 92
percent, respectively. The sensitivity (30 percent) and specificity (78 percent) of diffuse
reflectance spectroscopy alone is significantly lower. Combining fluorescence and diffuse
reflectance spectra did not improve the classification accuracy of an algorithm based on
fluorescence spectra alone. The difficulty in the study is the inability to determine the
biological basis of the differences observed in the fluorescence spectra of malignant and
nonmalignant tissues. Several groups have investigated the Raman spectroscopy
[Alfano, 1991, Frank, 1995, Frank, 1994] for diagnosing cancer, but to our knowledge, no
researchers have employed the combination of fluorescence, reflectance, and Raman
spectroscopies. We expect that the combination of these techniques, which we call multi-
modal spectroscopy, will provide a better overall accuracy, defined as the correct
prediction of each of the different pathologies.
This thesis will explore the application of DRS/IFS to the diagnosis of breast lesions and
will evaluate the combination of DRS/IEFS and Raman spectroscopic modalities in terms
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of diagnostic success with ex vivo data. DRS/IFS spectra of the tissue sample were
obtained, immediately followed by the collection of a Raman spectrum. Care was taken
in placing the Raman probe at the same site on the tissue as the FastEEM probe. The
tissue measurements were taken within half an hour of excision.
1.3 Objectives
The major goal of this thesis is to explore the usage of intrinsic fluorescence and diffuse
reflectance spectroscopies for diagnosing breast cancer. The research is performed in
several stages, which are examined in following chapters:
The goal of DRS/IFS data analysis is to develop an overall algorithm that
will distinguish among five pathologies. The algorithm is developed using
leave-one-out cross validation and logistic regression and includes
parameters from DRS (diffuse reflectance spectroscopy) and IFS (intrinsic
fluorescence spectroscopy).
Another direction of this research is the investigation of different
fluorescence excitation wavelengths. DRS/IFS data were collected via the
FastEEM instrument developed in the Spectroscopy Laboratory
[Motz,2002, Tunnell,2003]. The FastEEM delivers a sequence of ten laser
pulses (308- 480 nm) and two white light pulses to the tissue via an optical
fiber probe. Different excitation wavelengths excite different fluorophores
and probe different tissue depths. We utilize IFS data from three different
wavelengths to examine the differences in penetration depth in the breast
tissue. The information from the concentration of fluorophores, such as
NADH, collagen and others are expected to provide diagnostic
information about different pathologies that can be related back to breast
anatomy and histopathology. It is anticipated that the application of
different wavelengths provides us with additional diagnostic information.
Using an already developed chemical/morphological model of breast
cancer with Raman spectroscopy [Haka,2004], Raman spectra acquired
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from intact, ex vivo samples is examined in a prospective manner. The
chemical/morphological model is based on a linear combination of nine
basis spectra using an ordinary least-square minimization algorithm with a
non-negative constraint, as is explained in more detail in Chapter 5.
Additional goals include expanding our diagnostic algorithm to include
pathologies not observed in our ex vivo laboratory data, such as ductal
carcinoma in situ (DCIS).
The main goal of this study is to investigate and develop a multimodal
spectroscopy algorithm that combines Raman and DRS/IFS spectroscopic
information. In this phase of the research, the sensitivity and specificity of
each method are compared, with a focus on the similarities and differences
between the outliers obtained with either the Raman or DRS/IFS methods.
The results will shed light on the advantages of combining the two
techniques, and perhaps on the need for developing a combined Raman/
DRS/IFS probe.
13
Chapter 2. Breast Cancer
In order to develop a diagnostic algorithm for the early detection of breast cancer, it is
important to thoroughly understand the anatomy of breast tissue. Some of the work in this
chapter can be found in more detail in [Haka,2005, Rubin,1996].
2.1 Introduction and Epidemiology
Cancer is described as any malignant growth or tumor caused by uncontrolled division of
abnormal cells; it also may spread to different parts of body through the blood stream or
lymphatic system. In 2003 in United States, there were 211,300 females diagnosed with
breast cancer, which accounts for nearly one in every three cancers diagnosed in women.
In the same year, there were an estimated 39,800 deaths attributed to breast cancer,
including about 400 males [Jemal,2004]. There is a difference in the number of
incidences of breast cancer for major ethnic groups (breast cancer is slightly more
common in Caucasians). This phenomenon is associated with differences in breast
anatomy for different ethnic groups, socioeconomic status and lifestyle, which brings
about a difference in treatment and survival rate. The growth of breast cancer tumors is
often affected by the presence of estrogen and progesterone. The following risk factors
are a result from exposure to these hormones: over the age of 50, first pregnancy after age
30, not having children at all, menstruation before age 12, menopause after age 50. Also a
family history of the disease, a personal history of disease, a history of breast biopsy or
chest radiation, moderate alcohol use (2 to 5 drinks daily), obesity, and race are
considered risk factors.
Over the last several years the mortality rate has decreased slightly likely owing to early
diagnoses and improvements in treatment. The earliest diagnosis is accomplished via
abnormalities detected by mammography before anything can be felt by a woman or her
doctor during a breast examination.
14
The lack of glandular tissue in the male breast is the primary reason for the rarity of male
breast cancer. Because male breast cancer contributes only about one percent to the total
numbers of breast cancer, breast cancers in women will be the focus of this research
2.2 Breast Anatomy
The mature breast is made up of
secretory glandular tissue and
surrounding adipose tissue. Breast ribroadencma n
cystic disease
tissue extends from below the Lobule PecrtOa& MUS1leLabular cancer, winor
collarbone to the level of the sixth Ductl ca"c .ajor
Duct .et~.a Intercostal
or seventh rib, and from the L*a oua" "'"*
breastbone to the axilla. The nipple sease
connectivesmmam
and areola are covered by stratified tisau *tZA
Phyllde tor
squamous epithelium and they are
located in the center of the breast.
Fibrous connective tissue (fascia) Figure 2.1 Anatomy of the breast
lies between the breast tissue and
the skin, and separates breast tissue from the chest muscles. A schematic of the female
breast is shown in Figure 2.1 .[Rubin,1996] Axilary and intercostals arteries provide blood
to the breasts; axillary and intercostals veins carry blood away from the breasts. Breast
cancer cells can travel to the lungs through surface veins and metastatic tumors; breast
cancer cells can spread to the bone via intercostals veins to the vertebral veins network in
and around the spine.
The glandular tissue is composed of 15 to 20 lobes, or milk glands, connected to a
conduit of ducts that carry milk to the nipples. Each lobe is autonomous and connects to
its own excretory duct, which connects to the nipple. The lobes themselves are divided
into smaller units called lobules, which in turn are made up of acini. The lobules are the
functional, milk producing, units of the mammary parenchyma. The lobular units and the
ducts that connect them are separated from the stroma by a basement membrane, which
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composed of collagen. Two layers of fibrous ligaments (Cooper's ligaments) support the
mammary glands. These arise from stromal elements in the gland and insert into the skin
and pectoral fascia, holding the breast against the chest. The breasts lose their firmness
and take on a sagging appearance when these ligaments stretch with the age and multiple
pregnancies.
2.3 Normal Breast Tissue
The breast consists of three types of tissue: adipose (fat), fibrous, and glandular. The fatty
tissue and connective tissue make up the stroma - the tissue lying between the glands.
The fatty tissue encloses cells (adipocytes). The fibrous tissue contains collagen and
small amounts of glycosaminogycans. The majority of breast stroma consists of dense
fibroconnective tissue admixed with adipose tissue (interlobular stroma) containing
elastic fibers supporting large ducts.
2.4 Breast Pathology
Most breast diseases present as palpable masses, inflammatory lesions, nipple secretion
or mammographic abnormalities. Of the women with detected abnormalities,
approximately 30 percent are found to have no problems, 40 percent are diagnosed with
fibrocystic change, 13 percent have miscellaneous benign tumors, 7 percent have
fibroadenoma, and only 10 percent of women are diagnosed with cancer. Here we will
focus only on FCC (fibrocystic change) and on fibroadenoma.
Fibrocystic Chan2e
Multiple cut sections of breast tissue in Figure 2.2 display classic signs of fibrocystic
change, with blue-domed cysts and dense fibrosis (hence, the name fibro-cystic).
Fibrocystic change is a benign condition that can be described as fibrosis - formation of
fibrous tissue; adenosis - increase in number of ductules; or cyst formation - dilation of
ducts and lobules with semi-transparent fluid. These changes can occur alone or in any
combination. The cyst size often varies with the phase of menstrual cycle and can
16
.obular
of
Figure 2.2 Gross and histopathology slide with fibrocystic change
become quite tender when under tense pressure. Fibrocystic changes do not increase the
risk of developing cancer. However, if FCC produces palpable lumps, mammographic
densities or calcifications, or nipple discharge mimicking carcinoma, then it may come to
clinical attention.
Fibroadenoma
Fibroadenoma is the most common benign tumor of the breast. There are several other
types of benign tumors such as ductal epithelial hyperplasia (DEH), intraductal papiloma,
etc., though they occur at rates far lower than fibroadenoma. Many cases of
fibroadenoma occur in younger women. It is described as a new growth composed of
both fibrous and glandular tissues. Morphologically, fibroadenoma grows as a spherical
Figure 2.3 Gross and histopathology slide with fibroadenoma
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nodule that is usually circumscribed
and freely movable from the
surrounding tissue. Figure 2.3 displays
gross and histopathology slide of
fibroadenoma. Lesions diagnosed as
fibroadenoma show an accumulation
of collagen due to fibroblast
proliferation that results in expansion
of the stroma. Even though Figure 2.4 Gross breast carcinoma
fibroadenoma is a benign lesion, the
fact that it often grows rapidly resulting in significant morbidity causes it to be typically
excised. These tumors frequently occur in the upper outer quadrant of the breast. They
vary in size from less than 1 cm to giant forms of 10 to 15 cm in diameter. Most of them
are removed when they are 2 to 4 cm in diameter.
Cancer
Most breast cancer develops in glandular tissue, epithelium. Cancer is characterized by
abnormal cell proliferation as well as abnormal maturation of cells. Malignant cells tend
to reproduce even after they have doubled 50 or 60 times, so with time they form a
monomorphic tumor that is built up of billions of copies of the original cancerous cell.
Breast carcinoma is shown on Figure 2.4. A flowchart of the breast cancer "continuum"
from normal breast tissue to invasive cancer is shown in Figure2.5 [Haka,2005].
The earliest form of breast cancer, ductal carcinoma in situ (DCIS), develops solely in the
milk ducts. Malignant cells are still located within the ductules and have not broken
Normal - Hyperplasia -+ Atypical Carcinoma , Invasive
Hyperplasia in situ Cancer
(increase in (abnormal (cancer exists but (cancer exists
number of cells) increase in is confined to the and has spread
number of cells) ducts or lobules) beyond the ducts
and lobules)
Figure 2.5 Flowchart disDlavin2 the breast "continuum"
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Figure 2.6 Invasive ductal carcinoma. Gross and histopathology slide
through the basement membrane and into the stroma.
Currently women diagnosed with DCIS are treated with mastectomy followed by
radiation. It is now believed that many cases of low-grade DCIS and most of the cases of
high-grade DCIS progress to invasive carcinoma [Rubin,1996]. This fact once again
emphasizes the importance of proper early diagnosis and appropriate treatment.
The most common type of breast cancer, which accounts for 70-80 percent of cases, is
invasive ductal carcinoma (IDC). IDC develops from DCIS, spreads through the duct
walls, and invades the breast tissue. It can be seen in Figure 2.6.
The central white area on the picture of gross IDC is very hard and gritty because the
neoplasm is producing a desmoplastic reaction with lots of collagen. This is often called a
"scirrhous" appearance. There is also focal dystrophic calcification leading to the gritty
areas. Lesions diagnosed as infiltrating carcinoma exhibit significant hyperplasia and
often exhibit increases in collagen content due to fibroblast proliferation in response to
stromal invasion by the malignant epithelial cells. Lobular carcinoma in situ (LCIS)
consists of hyperplasia in the terminal breast ducts and acini. The cells are small and
round. Invasive lobular carcinoma (ILC) accounts for 5-15 percent of invasive breast
cancers. ILCs often have a diffusely invasive pattern causing tumors to be difficult to
detect by either physical examination or mammography. There are several other less
common types of breast cancer. The swelling of the breast, inflammatory breast cancer, is
an uncommon type of breast cancer. Its symptoms include an increase in the skin
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temperature, redness, and swelling of the breast. The skin may show signs of ridges and
welts or it may also have a pitted appearance.
2.5 Breast Cancer Screening, Diagnosis, and Treatment
Women between the ages of 20 and 39 should have a breast examination by a physician
every 3 years. After 40 years old, women should have a clinical breast exam and
mammogram annually. Mammography and ultrasound are techniques that allow many
cancers to be discovered at an early stage. They are considered as imaging techniques,
which rely on density changes in the breast to detect cancers.
2.5.1 Screening
Mammoraphy
Mammography is a non-invasive imaging procedure that uses x-rays to create images of
breast tissue [Dahnert,1999, Haka,2005]. During a mammogram, the breast is
compressed between two photographic plates that are used to record the attenuation of x-
rays as they traverse the tissue. Different tissues in the breast absorb different amounts of
x-rays, producing varying shades of black, gray, and white on the film. Fatty tissue
absorbs a relatively small amount of x-rays and thus appears black or dark gray. Normal
fibrous and glandular tissues contain water that causes absorption of a moderate amount
of x-rays and thus appear light gray. Dense breast
tissue, with more collagen, can make mammogram
evaluation difficult because the tissue can obscure small
cancers. Many mammograms show nontransparent
white specks. These are calcium deposits known as
calcifications and they are a key component that
radiologists look for in a mammogram. Radiologists are
looking for asymmetric densities - area in one breast
that has a distinctly different appearance than the same Figure 2.7 Mammogram
area in the other breast. The shape of a mass detected demonstrating speculated mass
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by mammography is important for differentiating benign and malignant lesions. A
mammogram is a screening test, not a diagnostic test, which is why mammography
cannot be an indicator of the cancer on its own [HST,2004]. The abnormalities found on
a mammogram must be examined with further tests. Unfortunately, in most cases further
testing shows masses detected via mammography to be benign, and in 10 percent of
cases, radiologists misread normal tissue as abnormal.
Ultrasound
Ultrasound, or ultrasonography, is a medical imaging technique that uses high frequency
sound waves and their echoes. The technique is similar to the echolocation used by bats,
whales and dolphins. It is performed with a transducer. During the ultrasound procedure a
radiologist spreads a gel on the skin of the breast and uses the transducer to direct sound
waves through and into the breast. Thus, this technique provides freedom in obtaining
images of the breast from any orientation. It can be used in determining if a mass is a cyst
or a solid lesion that may possibly be cancerous. Even though ultrasound has great
contrast, it lacks the spatial resolution of mammography. For this reason it is unable to
image small lesions or microcalcifications, which may be a sign of malignancy.
Therefore, ultrasound is not approved by the FDA as a screening tool for breast cancer
and is only used to aid mammography in detecting abnormalities in the
breasts. [Gordon,2002, Haka,2005]
2.5.2 Biopsy
Excisional Biopsy
Biopsy is the procedure of removing tissue from a potentially abnormal site previously
found by mammography, ultrasound, or by a physician for further investigation.
Traditionally, open excisional biopsies are performed under general anesthesia in the
operating room. A surgeon removes the entire lesion, which can vary in size from a few
centimeters to the entire breast (mastectomy). After removal the tissue is sectioned,
specially stained, and examined by a pathologist. Currently, a diagnosis by pathology is
considered the gold standard for diagnostic algorithm development.
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Needle Biopsy
In recent years, less invasive techniques such as
needle biopsy have been developed. Needle
biopsies are less intrusive than excisional biopsies
yet they provide the same diagnostic accuracy.
. steredtectic tableThe lump is localized with the aid of
mammography and ultrasound. During this Figure 2.8 Instrumentation used in
procedure the woman lies facedown on a special stereotactic biopsy procedures
table, as shown in Figure 2.8. Needle biopsies are performed in a radiologist's office on
an outpatient basis under local anesthesia. This whole procedure can be done in just few
minutes.
Fine Needle Aspiration (FNA)
Different needle biopsies use different sizes of needles. In cases where the doctor wants
to extract fluid from a cyst or cells from a solid lesion, they utilize very small needles of
20-25 gauge (0.89-0.51 mm). The procedure is performed under local anesthesia and
requires a small incision. The procedure takes a few minutes and typically leaves no
scarring and does not require stitches. FNA is the easiest method to provide pathologists
with a breast biopsy. Due to the small size of the needle used for FNA, the scarring
process will be quick, but as a result the evaluation of the suspicious lesion can be
incomplete. A study of fine needle aspiration found that 34 percent of patients were
insufficiently sampled and required more biopsies in the future.
Core Needle Biopsy
Core needle biopsies are similar to fine needle aspiration with the exception of the larger
size of the needle (14-18 gauge, 2.11-1.25 mm). Increasing the size of the needle enables
the doctor to obtain a larger sample that can lead to a better diagnostic accuracy and will
require a smaller number of biopsies in the future. During the core biopsy breast tissue is
removed while under FNA only cells and fluids are removed.
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2.5.3 Staging and Prognosis
Breast cancer has been divided into smaller groups in order to standardize comparisons of
results of various therapeutic modalities among clinics and guide treatment. The
American Joint Committee on Cancer Staging divides the clinical stages as follows
[Rubin,1996]:
Stage 0. Cancerous lesions diagnosed as DCIS or LCIS have a 5-year survival
rate of 92 percent.
Stage I. This stage includes invasive carcinoma with a size of 2 cm or less
without nodal involvement and without any distant metastases; the 5-year survival
prediction is 87 percent.
Stage II. As the cancer progress in size (invasive carcinoma 5 cm or less) and if
there are movable axillary nodes involved, but still there are no metastases, the 5-
year survavial rate drops to 75 percent.
Stage III. Different features of breast cancer development correspond to this
stage, such as a lesion that is greater than 5 cm in size; breast cancer with fixed
azillary nodes or that involves ipsilateral mammary lymph nodes; any breast
cancer with skin involvement, pectoral and chest wall fixation, edema, or clinical
inflammatory carcinoma, if distant metastases are absent. It relates to a 5-year
survival rate of 46 percent.
Stage IV. If the breast cancer already has distant metastases, the 5-year survival
rate is about 13 percent.
The older the patient with a single breast lesion, the more likely it is to be cancer. Tumor
size is another important prognostic factor also used in staging a lesion, as a larger tumor
increases the risk of axillary and systemic metastasis. However, although rare, very small
tumors are capable of distant metastasis. The course of treatment depends on both the
stage of the disease and the patient's preference. Treatment options include surgery,
radiation therapy, chemotherapy, hormone therapy, and immunotherapy. If no axillary
metastases are present, some patients may not receive systemic therapy, depending on the
characteristics of the tumor. Almost all women with one to three positive axillary nodes
receive some form of standard systemic treatment, either hormonal therapy or
chemotherapy. Women with four to nine positive axillary nodes are eligible for clinical
trials using high-dose chemotherapy. If ten or more nodes are positive, women are
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eligible for other experimental treatments, such as autologous bone marrow
transplantation.
2.5.4 Surgery
The combination of surgery with radiation and/or chemotherapy is the most common
treatment for breast cancer. Lumpectomy and mastectomy are both commonly performed
surgical procedures. A partial mastectomy, a lumpectomy, is the surgery of removing a
tumor from a breast. Depending on the case, lymph nodes may also be removed during
this procedure. To make sure that all of the cancerous cells are excised from the patient,
excised tissue is inked with different colors on all faces. If cancer cells are found
touching or near the inked regions, it is assumed that malignant cells are likely still
present in the patient. The color of ink identifies the region of the surgical cavity which
still had malignant cells. Simultaneously with inking excised tissue, the surgeon removes
about 6 small samples, called margins, from different spots of the lesion cavity. Margins
and the excised tissue are examined by a pathologist to decide if any cells can be
presumed present in normal tissue. In cases where those cells are found the doctor
recommends the patient undergo a re-excisional biopsy. Generally, lumpectomy
procedures take 60 to 90 minutes. Even in the case of clean margins (no cancerous cells
have been found in margins) women receive 6 to 7 weeks of radiation therapy in order to
eliminate the smallest possibility of remaining cancer cells.
There are three types of mastectomies: simple, modified radical and radical
mastectomies. A simple mastectomy includes removal of the breast tissue, skin and
nipple but rarely lymph nodes. A most common form of mastectomy is a modified radical
mastectomy, under which the entire breast is removed. Also, some amounts of lymph
nodes are removed from the underarm region, which is the reason for more difficulties
with the range of motion in the arm and shoulder on the operative side after the surgery.
Mastectomies require general anesthesia and must be done in the hospital. Patients have a
choice of getting breast reconstruction immediately following the mastectomy as a part of
the same surgery, or receiving it afterwards.
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2.5.5 Therapy
Radiation Therapy
Radiation therapy uses high-energy x-rays to destroy cancer cells. It is performed
externally or by radioactive "seeds" that are placed directly into the tumor, called
brachytherapy. The patient may be asked to go through radiation therapy in order to
shrink the tumor before surgery or she may be asked to undergo radiation after surgery to
destroy all the cancerous cells remaining in the breast, underarm, or chest wall, known as
adjuvant therapy. Radiation therapy is performed in a hospital or outpatient center.
Radiation treatment lasts for 6 to 7 weeks, and each treatment session takes a few
minutes.
Chemotherapy
Chemotherapy is a systemic treatment that travels throughout the body via the
bloodstream. It often relies on a combination of drugs to slow tumor growth and destroy
cancer cells. Drugs may be given to a patient orally or injected into the venous system.
Chemotherapy can be used before and after the surgery similar to radiation therapy for
the same reasons.
Hormone Therapy
The most effective and least toxic therapy currently available is endocrine manipulations.
Estrogen, a hormone produced by women's ovaries, promotes the growth of some breast
cancers, particularly those with detectable amounts of estrogen receptor protein.
Hormone therapy is based on blocking the effect of estrogen or lowering estrogen levels.
It can be prescribed to a patient before and/or after biopsy, as well as to treat cancer that
has spread or regenerated after treatment in the past.
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2.6 Summary
Breast cancer is the most common female cancer. The survival rate depends on early
diagnosis and the right treatment. Pathology is the gold standard for diagnosis, but it is
time consuming. Breast cancer is considered to be a heterogeneous disease, i.e. it is a
different disease in different women. Owing to the heterogeneity and complexity of the
breast, a good understanding of breast pathology is necessary for the correct development
of a diagnostic algorithm.
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Chapter 3. Theory and Instruments
The research presented in this thesis is focused on the application of diffuse reflectance,
intrinsic fluorescence, and Raman spectroscopies to diagnose breast cancer. The theories
have been explained in more detail in the theses of Abigail Haka [Haka, 2004] and
George Zonios [Zonios, 1998]. In this thesis, we will discuss only the key-points. For
more details refer to the works mentioned above.
3.1 Raman Scattering Theory
The Raman Effect was first discovered by C.V. Raman in 1928. For this discovery
Raman was awarded the Nobel Prize in Physics in 1930. The Raman Effect involves the
exchange of energy between light and matter. When light travels through a medium, the
scattering occurs over all directions and both the intensity and polarization of the
scattered radiation depend on the direction of observation. Most of the scattered light is
of the same wavelength as the incident photons. This type of scattering is elastic and is
called Rayleigh scattering. A small part of scattered light is inelastically scattered. The
Raman Effect is an inelastic scattering process in which photons incident on the sample
take energy from (Stokes) or transfer energy to (anti-Stokes) the sample's rovibrational
modes. Raman is a two-photon process that can be viewed as the simultaneous absorption
of an incident photon and emission of a Raman photon. The difference between the
energies of these two photons corresponds to the transition of the molecule from one
energy state to another. Since the energy level diagram is unique for every molecule,
Raman spectra are chemically specific. Individual bands in the Raman spectrum are
characteristic of specific molecular motions. Also, as Raman scattering involves a net
exchange between the radiation and the molecule, it is often classified as an active
process. The generation of the Stokes and anti-Stokes components are illustrated in
Figure 3.1.
27
WL S WL WAS
Stokes Anti-Stokes
f] WR
Figure 3.1 Energy level diagram of spontaneous Raman scattering: Stokes and Anti-Stokes
generation
The energy difference (hoR) between the incoming photon with frequency OL and the
scattered Stokes photon with frequency os matches a molecular vibration in a gas or
liquid, or a phonon in a solid Raman medium. When the scattered light has a lower
frequency than the exciting photon it is called the Stokes line (OS = (oL - oR). When the
scattered light has a higher frequency than the exciting photon it is called the anti-Stokes
line (OAS (OL + (OR)
The Stokes lines are usually much more intense than the anti-Stokes lines because in
thermal equilibrium the population of the excited state is much smaller than the
population in the ground state. At thermal equilibrium the fraction of the molecules in
one vibrational energy level relative to another is given by the Boltzman distribution:
NI 1  AE
N2  9 2  kT
where N2 and N1 are the numbers of molecules in a higher and lower vibrational energy
level, respectively; g2 and gi are the degeneracies of the higher and lower vibrational
levels respectively; AE is the energy difference between the higher and lower vibrational
energy levels; k is the Boltzman constant; and T is the temperature in degrees Kelvin.
The anti-Stokes Raman intensity becomes infinitely small relative to the Stokes Raman
intensity for high energy vibrations or low temperatures. Population in the higher energy
level is proportional to exp(-hoR/kT).
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3.2 Raman Instrument and Probe
The clinical Raman instrument, developed in the Spectroscopy laboratory, is illustrated in
Figure 3.2a. Light from an 830-nm diode is collimated by two cylindrical lenses, directed
through a bandpass filter, redirected by a gold-coated mirror and focused onto the Raman
probe excitation fiber by a lOxmicroscope objective.
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Figure 3.2 a)Schematic of the Raman spectroscopy system. b)Schematic of the Raman probe tip
The proximal linear array of collection fibers from the Raman probe are the input for the
f/1.8 spectrograph, which collimates the light before it is notch-filtered and focused onto
a slit, and then recollimated for dispersion by the holographic grating. Finally, the
dispersed light is focused onto a liquid-nitrogen cooled, back-illuminated, deep depletion
CCD detector, which is interfaced with a laptop computer. The schematic of the Raman
probe used in the study is presented in Figure 3.2b. The probe has a total diameter of 2
mm and a length of 4 m.
3.3 Diffusion theory
Diffuse reflectance spectroscopy (DRS), also sometimes known as elastic scattering
spectroscopy, is a non-invasive technique that uses the interaction of light with a sample
through absorption and scattering phenomena to produce a characteristic reflectance
spectrum that provides information about the structure and composition of the medium.
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Diffusion theory is appropriate in a medium dominated by scattering rather than
absorption so that each photon undergoes many scattering events before being terminated
by an absorption event. The photon has a relatively long residence time that allows it to
engage in a random walk within the medium.
Elastic scattering is the most prominent optical property of tissue. The scattering
coefficient, ps, which represents an average number of scattering events per unit length, is
in the range of pts=10-100mm-1 for soft tissue. This range indicates that light is scattered
several tens of times per millimeter of path length while traveling in tissue, i.e. it quickly
becomes diffusive. The angle-dependent scattering pattern of the scattering depends on
the scatterer size/wavelength ratio. Rayleigh scattering occurs when the scatters are much
smaller than the wavelength of light. In such a case, the scattering pattern is isotropic. In
the case when the scatterer size is much larger than the wavelength, scattering is highly
forward directed, which is the case in tissue.
Biological tissue is a complex and heterogeneous material. The exact origins of scattering
in tissue are not well known. Scattering arises from the microscopic variations and
inhomogeneities of the refractive index that correspond to various scattering centers.
[Zonios, 1998]. The angular distribution of the scattering is described by the scattering
phase function, p(O), which provides the probability of a photon to be scattered at an
angle, 0, with respect to the initial direction. The scattering coefficient is essentially the
cross-sectional area per unit volume of tissue. The reduced scattering coefficient is a
lumped property incorporating the scattering coefficient ps and the anisotropy g:
IIs' = ps(l - g), where g = 2r p(O)cos Osin OdO (2)
Anisotropy, g, is used to indicate how strongly forward-directed the scattering is. Typical
values for tissue are g = 0.8 - 0.95, which corresponds to average scattering angles
between 45 and 20 degrees, respectively. The purpose of ps' is to describe the diffusion
of photons in a random walk of step size of l/ps,' [cm] where each step involves isotropic
scattering. Such a description is equivalent to the description of photon movement using
many small steps 1/pts that each involve only a partial deflection angle 0 if there are many
scattering events before an absorption event, i.e., p'a << [s'. This is very appropriate and
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convenient for modeling multiple scattering processes where the light quickly becomes
diffusive.
The problem of scattering of a plane wave by homogeneous spherical objects is known as
Mie theory. Mie theory provides an exact solution for scattering of light with wavelength
X by a spherical object with diameter d and refractive index n that is located in a
surrounding medium with refractive index no. Experimental evidence [Zerull 1976]
indicates that by averaging over orientation and/or size, the scatter properties of
nonspherical particles can be equivalent to that of spheres, i.e. Mie theory can be applied.
In this study ps' was modeled using a power law in the following way:
pS'= AAB + (3)
where the first polynomial term represents Mie scattering and the second term represents
Rayleigh scattering. In this formula, A can be interpreted as the amount (or
concentration) of Mie scatterers, B is related to the sizes of the scatterers, and C is the
amount of Rayleigh scatterers. The exact physical meanings of these parameters are still
under investigation. However, upon analysis it was discovered that C is equal to zero,
which modified formula 3:
s=A-B (3a)
Absorption
Absorption is measured by means of the absorption coefficient, Pa, which is defined as
the amount of absorption present in units of inverse length. Water, being the major
component of soft tissue has negligible absorption in the visible range (<104 mm-I) [Hale
and Querry, 1973]. Tissue absorption, which depends on wavelength, is due to a number
of characteristic biochemical molecules. Strong absorption prevents photons from
engaging in an extended random walk. Typical values for the absorption coefficient in the
visible range are 0.005< pa< 5 mm- .
Nearly all types of tissue contain hemoglobin because its main function is to transport
oxygen from the lungs: a necessity for the metabolism and normal functioning of all
living tissue. Hemoglobin is a major absorber in the blue region of the visible spectrum.
Other biochemical compounds with characteristic light absorption in the visible range
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Figure 3.3 Absorption spectra for oxyhemoglobin and P-carotene
include P-carotene, bilirubin, and in the skin, melanin. Many other absorbers are present
in the tissue at much smaller concentrations and can be ignored. In this study,
oxyhemoglobin and P-carotene will be treated as the major absorbers of light in breast
tissue. Their absorption spectra are illustrated in Figure 3.3.
The total absorption coefficient, pa, can be expressed as a linear combination of the
extinction spectra of the two absorbers as follows:
pa = CHbo, - HbO, (A)± + eCP E() (4)
where cp is the concentration of P-carotene and c HbO 2 is the concentration of
oxyhemoglobin.
3.4 Fluorescence
Fluorescence is one of the categories of luminescence and occurs from electronically
excited states. The fluorescence lifetime is typically 10-9 s. It is a measure of the average
time between its excitation and its return to the ground state. Many fluorophores have
lifetimes on the order of nanoseconds. Figure 3.4 illustrates the fluorescence
phenomenon. A fluorophore is excited to a higher electronic level by absorption of a
photon. It relaxes quickly from a higher vibrational level to the lowest level of the excited
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Fiiure 3.4 Molecular energy diagram depicting fluorescence
state through nonradiative processes and then emits a photon to reach the ground state.
From this process it is clear that the energy of emission is typically lower than that of
absorption. As a result, fluorescence photons are typically at lower energies or longer
wavelengths than the exciting photon. This phenomenon was first observed by Sir G.G.
Stokes in 1852.
Fluorophores are divided into two general classes: intrinsic, which occur naturally, and
extrinsic, which are added to a sample that does not display the desired spectral
properties. Among biological molecules, fluorescence can be observed from reduced
nicotinamide adenine dinucleotide (NADH), oxidized flavins (FAD, the adenine
dinucleotide, and FMN, the mononucleotide), pyridoxal phosphate, and chlorophyll.
Fluorescence spectroscopy has been widely explored as an important medical diagnostic
technique. Promising results have been reported when tissue autofluorescence is used to
detect a diversity of diseases, such as
atherosclerosis in the aorta and the
coronary artery and dysplasia in the
colon and other tissues. A majority of TISSUE
the diagnostic methods employed
utilize empirical algorithms derived
from studying a limited number of
specimens. Such empirical algorithms Figure 3.5 Photon migration of fluorescence
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ignore the wealth of biochemical and/or morphological information contained in the
tissue spectrum. Part of the difficulty has been that fluorescence spectra observed from
optically thick tissue are distorted from the intrinsic spectra of individual fluorescence
chromophores by the interplay of factors such as scattering, absorption, geometry, and
tissue boundary conditions. A model that removes the distorting effects on the
fluorescence spectra of optically thick tissues allows connection of the clinically obtained
in vivo tissue spectra with their biochemically based fluorophores. Algorithms that
incorporate the effects of the intrinsic fluorescence - scattering, absorption, excitation
and collection geometries, and the tissue boundary conditions - must be developed in
order to move beyond the current empirical approaches. The algorithm determined from
the photon migration approach suggests that the distortion in a fluorescence spectrum can
be removed by measuring the diffuse reflectance spectrum over the same wavelength
range, and in the same manner as the fluorescence spectrum, and by applying the
information extracted from the diffuse reflectance spectrum to the fluorescence spectrum
in a well-defined manner.
The fluorescent photon is emitted isotropically and undergoes scattering on its way out of
the tissue. In the model it is assumed that the secondary fluorescence generated by the
fluorescent photons is negligible. Since in the photon migration model the photon path is
determined by g and p, the incident excitation photon and the fluorescent photon induced
by it will follow the exact same path in the above conditions. Figure 3.5. shows an
example of a photon path in which an incident photon is scattered n times along its path
and thus induces n fluorescent photons.
Assuming that g is constant over all wavelengths of the fluorescence spectrum, and
knowing that in the fluorescence event the photon is always emitted isotropically, the
effective anisotropy coefficient geff can be shown to be the average value of (N-1)
forward directed scattering events with anisotropic coefficient g and a single isotropic
fluorescence event with gfluorescence =0.
For a semi-infinite geometry and index-matched boundary conditions this expression can
be further simplified as [Zonios, 1998]:
F(2,, 2,)= #(,,, ){1 - R[a( ,), g,,, ]JR[a(L,.), ge,] (5)
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3.5 Optical Spectroscopy of BenignIMalignant Breast Tissues
The IFS spectrum can be decomposed into a linear combination of the spectra of
fluorophores associated with morphological structures in the tissue to provide diagnostic
information
The endogenous fluorophores present in breast tissue include tryptophan, reduced
nicotinamide adenine dinucleotide (phosphate) (NAD(P)H), flavin adenine dinucleotide
(FAD), and collagen. NAD(P)H and flavoproteins are indicators of metabolic activity
and have excitation/ emission maxima at 351/460 nm and 450/520 nm, respectively.
Collagen is the primary structural protein in the extracellular matrix. It has several
excitation/emission maxima, one of which occurs at 325/390 nm.
Gupta and Majumder et al. analyzed different data sets collected from the same set of
breast tissues ex vivo and showed that the emission spectra at excitation wavelengths of
340 and 488 nm and excitation spectra at emission wavelengths 390 and 460 nm exhibit
significant differences between normal, benign and malignant tissues. The fluorescence
was attributed to reduced nicotinamide adenine dinucleotide (NADH) and collagen.
Spectral differences observed in the fluorescence spectra of normal, benign and
malignant breast tissues can also be attributed in part to non-fluorescent absorbers and
scatters. Diffuse reflectance spectroscopy provides a direct measurement of the tissue
absorption and scattering [Gupta,1997, Majumder,1998] .
According to Majumder et al., the fluorophores responsible for the 340, 390, 440, and
520 nm emission bands are amino acids (tryptophan), structural proteins (collagen and
elastin), the co-enzyme (NADH), and flavins, respectively [Majumder,1998]. It is known
that the excitation spectra recorded from the breast tissue samples for 340, 390, and 460
nm emission consists of spectral bands with peaks around 290, 335 and 340 nm, which
are characteristic excitation peaks for tryptophan, collagen and NADH, respectively. The
larger intensities of the 340 nm band in the excitation spectra, corresponding to 460 nm
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emission, for cancerous tissues would suggest a larger concentration of NADH in
cancerous tissues as compared to benign tumors and normal tissues.
Also, it has to be noted that light excited at different wavelengths penetrates to different
depths. We define the optical penetration depth as the depth at which the power of light
incident on a tissue sample falls to l/e of its incident value. The sampling depth
characterizes the attenuation of both the excitation and the emitted light, which can be at
a longer wavelength, as in the case of fluorescence or Raman scattering. Raman signal,
achieved using 830 nm excitation wavelength, has larger penetration depth than IFS
signal excited at 340 nm or 308 nm wavelengths. Later this information will be used in
comparison of Raman and DRS/IFS modalities.
3.6 FastEEM Instrument and Probe
A clinical instrument for DRS/IFS studies, the FastEEM, has been developed in the MIT
Spectroscopy Laboratory. This instrument collects white light reflectance and
fluorescence excitation-emission matrices (EEM's) within a fraction of a second in order
to collect diffuse reflectance, intrinsic fluorescence spectroscopic, and light scattering
spectroscopy data.
Diffuse reflectance spectroscopy (DRS) provides information about the morphology and
biochemistry of the stromal tissue and epithelium, determining values of the absorption
and reduced scattering coefficients, pa(X) and ps'(X), respectively. In the case of breast
tissue measurements, we study stromal lesions. Incident white light (300 - 800 nm)
undergoes many scattering and absorption events as it propagates through the tissue, and
the emerging ("diffusely reflected") light exhibits prominent spectral features caused by
the interplay of scattering and absorption. DRS employs a mathematical model based on
the diffusion approximation of light propagation in tissue.
The collected fluorescence and reflectance spectra can be used to extract the intrinsic
fluorescence spectra (i.e., the fluorescence unaffected by tissue absorption and
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scattering). Intrinsic fluorescence spectroscopy (IFS) yields the relative contributions of
endogenous tissue fluorophores (e.g. NADH and collagen).
Light scattering spectroscopy (LSS), which is based on Mie theory, extracts epithelial
nuclear size distributions from white light reflectance spectra. Light that has been singly
scattered in the backward direction can be analyzed to provide the nuclear size
distribution. LSS can provide information on number density of nuclei, percentage of
enlarged nuclei as well as mean nuclear size. [Tunnell,2003]. The application of LSS
technique to diagnose breast cancer will be explored in the future.
A schematic of the FastEEM is presented in Figure 3.6a. It delivers a sequence of ten
laser pulses (308- 480 nm) and two white light pulses to the tissue via an optical fiber
probe (see below for details of the probe design). The same probe collects the white light
reflectance and fluorescence and delivers it to the entrance slit of a diffraction grating
spectrometer where it is dispersed onto an intensified CCD detector. All ten laser-induced
emission spectra and the two white light reflectance spectra are collected in
approximately 0.3 s. Several of these acquisitions can be averaged together to increase
the signal-to-noise ratio (SNR). Previously, we found that the acquisition of five
measurements provides sufficient SNR in most tissues, making a typical acquisition time
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Figure 3.6 a) FastEEM clinical spectrophotometer. b) Schematic diagram
of the distal tip of the optical fiber probe
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on the order of 1.5 s. The optical fiber probe, which is used for light delivery and
collection, is illustrated in Figure 3.6b. It is in the form of a flexible catheter, with an
overall length of over 3 m and a diameter of approximately 1.2 mm.
3.7 Summary
In this chapter the theories behind the spectroscopic techniques employed in this work,
DRS, IFS and Raman, were presented. The theories are explained in more detailed in
[Haka, 2005] and [Zonios, 1998]. A brief overview of the instrumental design and
collected data was also presented. The data obtained with Raman spectroscopy will be
analyzed in a prospective manner based on the algorithm developed by Abigail Haka.
DRS and IFS will provide additional information on the chemical composition of the
tissue.
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Chapter 4. DRS/IFS
In 2004, my colleague, Abigail Haka, and I collected DRS/IFS and Raman spectroscopy
data on 105 samples from 25 patients during an ex vivo study at University Hospitals
Cleveland in collaboration with Drs. Fitzmaurice, Shenk, and Wang. This study was
undertaken to investigate the use of these spectroscopic techniques for the diagnosis of
breast cancer. All studies involving human tissue were approved by the University
Hospitals of Cleveland and Case Western Reserve University Institutional Review Board
and the Massachusetts Institute of Technology Committee On the Use of Humans as
Experimental Subjects. Informed consent was obtained from all subjects prior to the
surgical procedures.
Measurements were taken in the frozen pathology room within half of an hour of tissue
excision. We obtained reflectance and fluorescence spectra from the specimens with the
FastEEM instrument first, followed by collection of Raman spectra with the clinical
Raman instrument. Care was taken in placing the Raman probe at the same site on the
tissue as the FastEEM probe. Overall, we obtained 223 spectra (approximately two
spectra per specimen). After the DRS/IFS and Raman data were taken, breast specimens
were fixed and given to a pathologist for a diagnosis. The exact spot of probe placement
was marked with ink to aid in our comparison of spectroscopy and pathology. The
pathologies of the specimens included 33 normals, 59 fibrocystic changes (FCC), 9
fibroadenomas, 13 ductal carcinoma in situs (DCIS), and 9 infiltrating ductal carcinomas
(IDC), as determined by Dr. Fitzmaurice, a board-certified pathologist.
The focus of this chapter is on the development of the diagnostic algorithm for DRS/IFS.
Subsequent chapters will focus on the use of a previously developed diagnostic algorithm
for the Raman data set, and the development of a diagnostic algorithm using combined
information from DRS/IFS and Raman spectroscopy.
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4.1 Data Processing
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Figure 4.1 a) a representative DRS spectrum and fit; b) representative IFS spectra
obtained with 340 nm excitation. The original spectrum acquired from breast tissue is
in blue and the contributions of NADH (green) and collagen (black) were found via
multivariate curve resolution (MCR)
Reflectance spectra are analyzed using the diffusion approximation to extract tissue
morphological properties such as scattering, oxidized hemoglobin concentration, and P-
carotene concentration. The intrinsic fluorescence photon-migration model was used to
correct the fluorescence spectrum for distortions introduced by tissue absorption and
scattering. This corrected spectrum was then used to extract the contributions of the
biochemical tissue constituents NADH and collagen. Examples of DRS and IFS spectra
are displayed in Figure 4.1. The basis spectra used to model the IFS data shown in
Figure 4.1 b were extracted using
1 Norm multivariate curve resolution
0.9 FCC
0.8 " Fodenom (MCR), an iterative statistical
technique that will be discussed
further in section 4.2.
0.4 Figure 4.2. displays average IFS
0.3 data from each of the pathologies
encountered in this study.
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0 Differences are observed even
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wavelength, nm without a detailed analysis. The
Figure 4.2 normalized intrinsic full width at half-maximum
fluorescence spectra of breast tissue at
340 nm excitation. Peak at 680 nm (FWHM) is largest for IDC and
represents second order laser peak
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then decreases for fibroadenoma, DCIS, FCC and is smallest for normal tissue. A large
FWHM possibly indicates a higher concentration of NADH.
Three different excitation wavelengths (308, 340, and 360 nm) are analyzed in order to
reveal different fluorophores that could each provide information useful to a diagnostic
algorithm. Also, 400 nm excitation wavelength was analyzed, but information from this
wavelength did not provide any diagnostic importance. Table 4.1. presents an overview
of fluorophores that may be present in the breast tissue and fluoresce at particular
excitation wavelengths. However, upon analysis it was discovered that some of these
fluorophores are not present at high enough levels in our samples to be detected. These
include tryptophan excited at 308 nm, elastin excited at 340 nm, and porphyrin excited at
360 nm.
Excitation wavelength
308 nm 340 nm 360 nm
NADH NADH NADH
Fluorophores Collagen Collagen Collagen
Tryptophan Elastin FAD
Porphyrin
Table 4.1 Fluorophores at different excitation wavelengths
Representative spectra of DRS and IFS collected with different excitation wavelengths
are illustrated in Figure 4.3. Not all of the data collected were subsequently used for
analysis. Specifically, DRS data with overall reflectance less than 1 percent were
excluded because of the inability to use this information to process the fluorescence data
to obtain the intrinsic fluorescence. An example spectrum that was excluded from our
data set is shown in Figure 4.4. Furthermore, though most of the fits are observed to be
adequate, in cases of high oxyhemoglobin concentration, the region between 660 - 750
nm fits less well. We believe this to be a result of the fitting procedure and is a topic that
requires further investigation at a later date.
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4.2 MCR Analysis
In order to investigate the physical meaning of intrinsic fluorescence parameters, a
chemical study was performed in the Spectroscopy Laboratory using the FastEEM
instrument. The purpose of this study was to ensure that the fit coefficients resulting from
an MCR analysis have physical meaning. To test this assumption, fluorescence spectra
obtained from pure components (elastin, FAD, tryptophan) were used to fit data obtained
from mixtures of these pure components using ordinary least squares (OLS) fitting to
confirm linearity. Once the system was shown to be linear, parameters obtained from
MCR were used to fit the mixture data and the resulting fit coefficients compared to
expected values. Further, we examined whether the initial guess spectra used as inputs in
multivariate curve resolution affected these results, as will be discussed in more detail
below.
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Figure 4.5 Examples of pure
component spectra of elastin, and FAD
at 340 nm, also tryptophan at 308 nm
excitation are shown in red and the
previously collected basis spectra from
tissue that correspond to these
fluorophores are shown in blue.
FAD, tryptophan, and elastin were
dissolved in water for two hours.
Calibration spectra were collected to
ensure the DRS/IFS system was
operating correctly. Examples of
fluorescence spectra collected from
elastin, and FAD at 340 nm excitation
wavelength, and tryptophan at 308 nm
excitation are compared with the basis
spectra previously collected from
tissue in Figure 4.5. We observe that
the peak intensities of the spectra
collected from tissue are shifted to the
blue region compared to spectra
collected from pure chemicals. This
shift in emission wavelength is
expected because there are different
microclimates, which means that
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Figure 4.6. Mixture data: FAD, elastin and tryptophan; a) 1:1:1 concentrations ; b)
2:2:1 concentrations. resoectivelv. data is shown in blue. fit is in red
different fluorophores present in the tissue and interact with each other, in the tissue that
modify the spectral characteristics of the fluorophores [Richards-Kortrum, 1996].
Mixtures of FAD, elastin and tryptophan were created in concentration ratios of 1:1:1,
1:2:1, and 2:2:1. As expected, a linear combination of the spectra from pure components
weighted according to their concentration ratios fit the data well, thus confirming system
linearity. Representative spectra and fits are shown in Figure 4.6.
-pure component
basis spectrum
MCR from pure
MCR from basis
-- --- --- --- --
400 500 600 7
wavelength, nm
Figure 4.7 FAD: pure (blue), basis spectrum (red),
MCR from pure (green), MCR from basis spectrum
(black)
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Figure 4.8 MCR from pure components for fitting mixture data: FAD, elastin; a) 1:2
concentrations: b) 1:3 concentrations. resoectivelv. data (blue). fit (red)
MCR calculates basis spectra by minimizing the fitting error of a given spectrum using an
initial guess spectrum as the input. For the following analysis we extracted MCR basis
spectra twice: once using the pure component spectra as the initial guess and once using
basis spectra that were extracted from tissue measurements made by Irene Georgakoudi
as an initial guess. The basis spectra that MCR calculates are referred to subsequently as
MCR components. Although the original spectra were noisy, we were able to achieve
good fits regardless of the initial guess spectra used in MCR. Figure 4.7. shows the FAD
spectrum of the pure chemical along with its respective basis spectra obtained from tissue
measurements and the MCR components extracted using different initial guess spectra.
The resulted MCR spectra are practically identical, which suggests that minimization of
the fitting error does not rely heavily on the initial guess spectrum. This is ideal as it is
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Figure 4.9 MCR from basis spectra for fitting mixture data: FAD, elastin: a) 1:2
concentrations; b) 1:3 concentrations, respectively. data (blue), fit (red)
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difficult to know the exact spectral shape of the various fluorophores present in tissue
owing to the different tissue microclimates. The data from mixtures of FAD and elastin in
ratios of 1:2 and 1:3 are illustrated in Figure 4.8 along with fits obtained from MCR
components that used pure component spectra as the initial guess spectra. The fit
coefficients for a 1:2 ratio of FAD:elastin were 0.343 and 0.657, respectively. The fit
coefficients for a 1:3 ratio of FAD:elastin were 0.255 and 0.745, respectively. The error
was no more than 3 percent.
The same data from Figure 4.8 is displayed in Figure 4.9 with fits derived from MCR
components that used the tissue basis spectra as the initial guess spectra. The fit
coefficients for a 1:2 ratio of FAD:elastin were 0.356 and 0.644, respectively. The fit
coefficients for a 1:3 ratio of FAD:elastin were 0.255 and 0.745, respectively. In this
case the error was no more than 7 percent.
From this analysis we can conclude that in a simple system MCR is capable of obtaining
reasonable fit coefficients with a physical meaning from spectra of mixtures.
Based on the results of this study we analyzed IFS spectra of the ex vivo tissue using
MCR components. The basis spectra taken from separate tissue measurements were used
as the initial guess spectra. The basis spectra subsequently obtained using MCR are
thought to represent NADH and collagen because they have similar, though not identical,
lineshapes to the spectra of commercially available NADH and collagen. The lineshape
and the wavelength maximum of a fluorescence peak obtained from a solution of a pure
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Figure 4.10 Comparison of basis spectra vs. MCR components excited at 340
nm. Basis spectra (red); MCR (green)
46
component is known to be different than that obtained from the same component in a
different chemical environment, such as tissue. [Shafer-Peltier,2001] A comparison of
basis spectra vs. MCR components for 340 nm excitation is shown in Figure 4.10.
4.3 Algorithm Development
The DRS/IFS algorithm was developed using leave-one-out cross validation and logistic
regression. The desired algorithm must be able to distinguish among the 5 major
pathologies. From an examination of breast histopathology, it is known that normal breast
tissue consists mostly of adipocytes (fat) while the progression of malignancy includes an
increase in the amount of collagen. Therefore, we expect that normal tissue can be
separated from the remaining pathologies by the relative presence of collagen and P-
carotene, which is fat-soluble. Also from histopathology, fibroadenoma displays an
increased cellular density. Because the parameter A is representative of the number of
scatterers in the tissue, we expect fibroadenomas to have a relatively high A parameter.
Furthermore, we expect the NADH contribution, which is representative of cellular
metabolism, to be less than that from cancerous tissue.
By maximizing the sensitivity and specificity of each stage of the algorithm we were able
to identify the diagnostic parameters that can distinguish between pathologies in the
breast tissue. The diagnostically-relevant parameters from DRS were found to be P-
carotene, oxyhemoglobin, and the scattering A parameter. The diagnostically-relevant
parameters from IFS were found to be the fit coefficients for NADH at 340 nm excitation
and the fit coefficients for collagen at both 340 and 360 nm excitation wavelengths.
However, careful examination of the collagen fit coefficients obtained with 340 and 360
nm excitation revealed that only the results from one wavelength were necessary.
Because of the slight difference in wavelength between 340 nm and 360 nm, the
penetration depths of the light is not sufficient to result in different sampling volumes.
However, there is enough variation between the fit coefficients at both wavelengths that
averaging them does not provide benefit. This finding is quite important as the number
of diagnostic parameters should be minimized in order to prevent overfitting the data set.
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Figure 4.11 Schematic diagram of overall diagnostic algorithm
Therefore, the diagnostic parameters from IFS were reduced to NADH and collagen at
340 nm excitation.
The diagnosis is accomplished in a sequential manner. Normal tissue is first diagnosed
and removed from the remaining samples, followed by the diagnosis of fibroadenoma,
FCC, and then by the diagnosis of malignant lesions (DCIS and IDC), as depicted in
Figure 4.11. This algorithm can be implemented in "real time".
The scatter plots and decision lines for each step of the diagnostic algorithm are shown in
Figure 4.12. Figure 4.12a shows that P-carotene versus collagen can separate normal
tissue from the rest of the pathologies. After normal tissue was excluded from
subsequent steps, fibroadenoma was separated from FCC and IDC using NADH versus
the A parameter, as shown in Figure 4.12b. Finally, FCC was distinguished from cancer
using collagen versus oxyhemoglobin, as shown in Figure 4.12c. In the latter plot, three
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Figure 4.12 Discrimination of pathologies using DRS and IFS parameters
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diagnostic parameters se, % sp, %
Normals vs. rest of diagnosis? -carotene collagen@340 90.5 84.3
Fibroadenoma vs. rest(no normals) A NADH@340 100 100
FCC vs. IDC Hb collagen@340 100 97.9
Table 4.2 Sensitivity and specificity using DRS/IFS algorithm
samples (6 spectra) classified as FCC were misdiagnosed as cancer. Two out of those
three data samples were previously misclassified as normals. With this knowledge, the
sensitivity and specificity of each step are summarized in Table 4.2.
Table 4.3 compares the pathological diagnosis of each sample with the diagnosis from the
DRS/IFS algorithm developed for our data set. The sensitivity and specificity for the
separation of cancerous and non-cancerous pathologies are 100% and 95.8%,
respectively. The overall accuracy (correct prediction of each of the pathologies) is
87.6% (92/105). We note that although we have 100% sensitivity there are only 9
malignant samples.
During the clinical study we also obtained spectra from specimens that were later
diagnosed as DCIS. A total of 15 specimens were analyzed in the same sequential
manner as explained above. Despite a great deal of effort we were unable to distinguish
DCIS from the rest of the pathologies. An example scatter plot of two diagnostic
parameters, collagen and 0-carotene, for all of the pathologies is shown in Figure 4.13.
The DCIS lesions are seen to fall in all the parts of the schematic, making it impossible to
separate them from the rest of the diagnoses. One possible explanation for this failure
could be the small number of cancerous cells in the tissue that precluded proper
measurement. Further studies will be conducted in order to solve this problem.
Pathology Normal Fibrocystic Fibroadenoma Invasive
TMS Change Carcinoma
(32 samples) (55 samples) (9 samples) (9 samples)
Normal 27 7 0 0
Fibrocystic Change 2 47 0 0
Fibroadenoma 0 0 9 0
Invasive Carcinoma 3 1 0 9
Table 4.3 Comparison of pathologic diagnosis with that of the DRS/IFS diagnostic
algorithm for ex vivo specimens. The DRS/IFS diagnostic algorithm resulted in an
overall accuracy of 87.6% (92/105)
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Figure 4.13 Scatter plot for distinguishing amongst various pathologies including DCIS.
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4.4 Discussion
This pilot study is the first from our laboratory to use diffuse reflectance and intrinsic
fluorescence spectroscopies to examine breast cancer ex vivo. This study clearly
demonstrates the feasibility of DRS/IFS as a clinical tool for breast cancer diagnosis.
Although the results of this study demonstrate the potential benefits of DRS/IFS, it also
reveals its weakness, as DRS/IFS was not able to separate DCIS from the rest of the
diagnoses. Further investigations will be conducted that will better elucidate the
advantages and limitations of DRS/IFS as well as provide a better understanding of the
physical meanings of the diagnostic parameters.
50
Chapter 5. Raman Spectroscopy
We apply Raman spectroscopy to ex vivo samples in order to diagnose normal, benign
and malignant female breast tissue using a diagnostic algorithm previously developed in
our laboratory. Data were collected within half an hour of tissue excision and
immediately following DRS/IFS data collection. A total of 105 tissue samples from 25
patients are examined.
5.1 Raman Analysis
As stated in Chapter 3, Raman spectroscopy is a technique capable of providing accurate
chemical information of a tissue sample. There are a large number of Raman active
molecules in breast tissue and their spectral signatures are sharp and well defined.
Previously, we have developed a chemical/morphological model of breast tissue [Shafer-
Peltier,2001]. The Raman spectra, sampling a volume of 1 mm 3, are fit to a linear
combination of the basis spectra using an ordinary least-squares minimization algorithm
with a non-negative constraint. The following basis spectra are used in the algorithm: cell
cytoplasm, cell nucleus, fat, beta-carotene, collagen, calcium hydroxyapatite, calcium
oxalate dehydrate, and cholesterol-like lipid deposits. The Raman basis spectra are shown
in Figure 5.1.
Epithelial cell cytoplasm
Cell nucleus
Fat
A-carotene
Collagen
Calcium hydroxyapatite
-A Calcium oxalate dihydrate
Cholesterol-like
600 800 1000 1200 1400 1600 1800
Raman shift (cm')
Figure 5.1 Raman morphological model basis spectra
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Figure 5.2 Bar graph displaying the average composition of samples diagnosed as normEf,
fibrocystic chang 1g , fibroadenomE , and infiltrating ductal carcinoma I .
The fit coefficients, given by the model and normalized to sum to one, represent
contributions from chemical components and morphological features to the microscopic
tissue spectrum. Figure 5.2 illustrates a histogram of the average fit coefficients
associated with normal tissue, fibrocystic change, fibroadenoma, and infiltrating ductal
carcinoma. The fit coefficients of the normal breast indicate that it predominantly
consists of fat. This is consistent with breast pathology, as normal breast tissue is largely
made up of adipocytes cells containing copious amounts of cytoplastic fat, and adipose
tissue has a relatively large Raman scattering cross-section. The amount of collagen
increases in all abnormal breast pathologies. This happens because lesion formation is
often accompanied by scarring process - fibrosis, characterized by an accumulation of
collagen.
5.2 Data Measurements and Processing
Data were acquired via a clinical Raman system and Raman optical fiber probe. The
average laser excitation power was approximately 150 mW. No tissue damage was
observed at this power. The acquisition time varied depending on signal intensity and
ranged from 0.5 to 2 seconds. The spectrum of toluene was used to calibrate the
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instrument from day to day. The tissue fluorescence background was modeled with a
sixth-order polynomial and removed prior to data analysis.
5.3 Diagnostic Algorithm
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Figure 5.3 Scatter plot displaying the fat and collagen content for all pathologies
encountered in this study. Normal (rhombuses), fibrocystic change (squares),
fibroadenoma (stars), infiltrating carcinoma (circles).
Data were analyzed using the diagnostic algorithm previously developed on fresh-frozen
tissues in our laboratory, as shown in Figure 5.3. Application of this algorithm in a
prospective manner resulted in a sensitivity of 88.9 percent, correctly diagnosing 8 out of
9 IDCs, and a specificity of 90.6 percent for cancerous versus non-cancerous tissue.
This corresponds to an overall accuracy of 81 percent, (85/105). The limited number of
cancerous samples (9 IDCs) greatly influenced the sensitivity of our model. Table 5.11
represents a summary of the prospective use of the Raman diagnostic algorithm
5.4 Discussion
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Pathology Normal Fibrocystic Fibroadenoma Invasive
Raman Change Carcinoma
(32 samples) (55 samples) (9 samples) (9 samples)
Normal 30 7 0 0
Fibrocystic Change 2 41 0 0
Fibroadenoma 0 3 4 1
Invasive Carcinoma 0 4 5 8
Table 5.1 Comparison of pathologic diagnosis with that of the Raman
diagnostic algorithm for ex-vivo specimens. The DRS/IFS diagnostic
algorithm resulted in an overall accuracy of 81% (85/105)
The Raman algorithm remained quite robust when applied in a prospective manner.
However, this technique failed often for the diagnosis of fibroadenoma with 4 out of 9
specimens misclassified as cancerous. At the same time, it must be noted that due to the
nature of fibroadenoma, discussed in Chapter 2, lesions classified as such must be
excised. Thus, Raman spectroscopy, while having difficulty distinguishing between
fibroadenoma and cancerous lesions, can identify the lesions that must be removed from
the body.
This Raman diagnostic algorithm was developed to distinguish between four pathologies
at once, and did not include DCIS. An attempt was made to diagnose DCIS specimens
without changing the Raman algorithm, but it did not succeed. Studies to incorporate
additional fit coefficients and intensity information into the diagnostic scheme are
currently underway with the hope that it will aid in diagnosis. However, further work
needs to be done in order to properly distinguish among cancerous pathologies. It is clear
that additional model parameters need to be investigated to achieve this goal.
Finally, this analysis excludes patients who have undergone pre-operative chemotherapy
or who are undergoing re-excision surgery. Such patients harbor pathological tissue
changes that we have not previously examined. Pre-operative chemotherapy is used to
decrease the size of a large tumor and commonly a tumor is replaced by loose fibrosis.
This explains why we see an increase in collagen in all of the specimens from patients
who were treated with chemotherapy. If a patient already had an excisional biopsy and is
'54
undergoing a re-excisional surgery it is expected that the amount of collagen will be
increased as a result of the scarring process. These two pieces of information are very
important because our Raman analysis is based on the amount of collagen and fat present
in the breast tissue. The data from pre-operative and re-excisional chemotherapy biopsies
need to be analyzed separately from the rest of the data and a new diagnostic algorithm
developed. This will be accomplished in the near future.
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Chapter 6. Multi-Modal Spectroscopy
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Figure 6.1 Comparison of Raman collagen vs. DRS/IFS collagen
The promising results that were obtained using DRS/IFS and Raman spectroscopic
techniques separately raised the possibility of further improving our diagnostic
capabilities by combining the respective information into one diagnostic algorithm. Once
again, we used the data set from the clinical study performed in Cleveland, OH. In
developing the MMS algorithm, only parameters that were diagnostic in each of the
modalities were used. The diagnostic parameters from DRS/IFS include A, which
represents the amount of scatters, oxyhemoglobin, _-carotene, and NADH and collagen
with 340 nm excitation wavelength. The parameters from Raman Spectroscopy are the
fit coefficients for fat and collagen. Both of the modalities are sensitive to collagen.
However, because each uses a different wavelength of light (Raman at 830 nm and
DRS/IFS at 340 nm), the sampling depths are different. As it was mentioned in the
Chapter 3, Raman penetrates deeper than IFS excited at 340 or 360 nm wavelength.. This
fact explains why collagen fit coefficients extracted via Raman spectroscopy do not
strongly correlate with collagen fit coefficients extracted using DRS/IFS, as seen in
Figure 6.1.
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Figure 6.2. Scatter plots for three steps of Multi-Modal Diagnostic algorithm
In order to distinguish among each of the pathologies, leave-one-out cross validation and
logistic regression were implemented on the set of data. Because of the fact that more
than two parameters must be used to separate all 4 of the pathologies, the analysis was
performed in a sequential fashion in the same manner as the DRS/IFS algorithm. Figure
6.2 displays the scatter plots and decision lines for each of the three steps performed in
order to achieve separation of the pathologies. In the DRS/IFS diagnostic algorithm
developed in Chapter 4, 2 normals were misdiagnosed as FCC and 3 normals
misdiagnosed as IDC. By introducing a parameter from the Raman model to the first step
of the analysis, which separates out normal pathologies, and incorporating it with the
DRS/IFS parameter of oxyhemoglobin, we achieve a greater number of correctly
diagnosed normals. Only two remain misdiagnosed as FCC, a benign condition. The two
subsequent diagnosis steps remain identical to that used in DRS/IFS because in the
Pathology Normal Fibrocystic Fibroadenoma Invasive
Multimodal Change Carcinoma
(32 samples) (55 samples) (9 samples) (9 samples)
Normal 30 4 0 0
Fibrocystic Change 2 49 0 0
Fibroadenoma 0 0 9 0
Invasive Carcinoma 0 2 0 9
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Table 6.1 Comparison of pathologic diagnosis with that of the MMS
diagnostic algorithm for ex vivo specimens. MMS diagnostic algorithm
resulted in an overall accuracy of 92.4% (97/105)
second step all 9 fibroadenoma lesions are correctly diagnosed, while in the third step
both DRS/IFS and Raman failed for the same two samples. The fact that both modalities
missed the same limited number of samples suggests a possible registration error, which
needs to be clarified with the pathologist. Table 6.1 provides an overview of the MMS
algorithm performance. This algorithm improves the number of correctly diagnosed
normal and fibrocystic changes over that from either DRS/IFS or Raman modalities.
Additionally, a fewer number of pathologies are misclassified as cancerous, which is an
obvious benefit in that it increases the sensitivity and overall accuracy of this technique.
6.2 Discussion
The results of this study clearly show that a combination of diffuse reflectance, intrinsic
fluorescence, and Raman spectroscopies provide results better than that obtained from
either technique, as shown in Table 6.2. By improving the sensitivity and specificity for
malignant versus non-malignant lesion of our techniques we will provide doctors with the
ability to achieve an accurate diagnosis in real time.
Raman FastEEM Multimodal
Sensitivity 88.90% 100% 100%
Specificity 90.60% 95.80% 97.90%
Overall
acuracy 81% 87.60% 92.40%
Table 6.2. Comparison of three different techniques. Multi-modal technique provides
better sensitivity and specificity, as well as overall accuracy
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Chapter 7. Future Directions
This chapter focuses on the future of Raman, DRS/IFS and Multi-Modal spectroscopies
in breast cancer diagnosis and treatment. With the successful demonstration of ex vivo
DRS/IFS and MMS modalities, there are many clinical applications that can be
addressed. These clinical studies will be accompanied by a validation of our diagnostic
algorithm and the introduction of new pathologies into our data set. Some of the basic
experiments will focus on quantitative analysis and spectral refinement. Experiments on
determination sampling depth must also be performed in order to clarify the physiological
meaning of the diagnostic parameters used in DRS/IFS and MMS algorithms.
7.1 Diagnostic Algorithm Validation and Extension
DRS/IFS, Raman and MMS diagnostic algorithms must be modified to identify DCIS
and possibly other pathologies that are present in enough quantity in the data set. As
stated previously, our MMS diagnostic algorithm uses the fit coefficients of collagen
obtained with the Raman modality to separate normals from the rest of the diagnoses. As
illustrated in Figure 6.2.a, the decision line is nearly horizontal, which indicates that only
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Figure 7.1 Collagen fit coefficient excited at 830 nm for
different pathologies.
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the collagen content from the Raman technique contributes to the diagnostic algorithm.
Figure 7.1 is a boxplot, which illustrates the average values (red line), the interquartile
range, which is the difference between the 75th and 25th percentile of the data, (blue
box), and outliers (red plusses), of collagen content for each pathology. Given that a
clear separation of normals from the other pathologies is possible based on this one value
alone, the algorithm may be redeveloped in the future to possibly gain a diagnostic
advantage. Previously, the collagen content from DRS/IFS was analyzed in this manner
but did not show the same success. This is likely because of the different probing depths
of the DRS/IFS and Raman modalities; DRS/IFS could not sample deep enough into the
tissue to obtain a meaningful collagen content. Based on this finding, the diagnostic
algorithm for Raman spectroscopy may be modified by rationing the fit coefficients for
fat and collagen and plotting them versus a third parameter such as cell nucleus content.
We hope this modification to the algorithm will allow us to correctly identify DCIS
pathologies.
The results of the DRS/IFS and especially the MMS diagnostic models presented in this
thesis are promising. However, because they were based on a pilot study and derived in a
cross-validated manner, new clinical studies with a greater number of patients must be
completed in order to validate the diagnostic algorithms. This clinical study will be
undertaken after the construction of an MMS instrument that will have features of both
the Raman and DRS/IFS modalities. Currently the FastEEM instrument for DRS/IFS
employs 10 different excitation wavelengths, as discussed in Chapter 3. Only one
wavelength was ultimately incorporated into our diagnostic algorithm, which means that
we can greatly simplify our FastEEM instrument. However, because our laboratory does
not focus exclusively on breast tissue (artery, oral and other organs are also being
studied), we will develop an instrument with three excitation wavelengths - 308, 340, and
440 nm - to accommodate all organs that are currently under investigation.
60
7.2 Quantitative Study
Our Raman optical probe provides a reproducible geometry for data collection, allowing
us to examine spectral data that has not been normalized. Working with unnormalized
data, we can obtain quantitative information by incorporating the Raman scattering cross-
sections of the model components into the data analysis routine.
In this study, data will be acquired from thin sections of fresh-frozen breast tissue using
our Raman microscope. This data will be acquired using a low magnification objective to
ensure that the spectroscopic signal is representative of the entire breast tissue section.
Data will be collected for a long period of time to ensure high signal-to-noise ratio
Raman data. After spectroscopic data is collected, each thin section of breast tissue will
be examined by a pathologist. A combination of staining techniques and morpholometric
analysis will be used to obtain an estimate of the volume occupied by each morphological
feature represented in our Raman spectral model. These volumes will then be correlated
with the fit coefficients of the corresponding spectra. In this manner, the contribution of
each morphological component to the overall Raman signal level can be found.
Additionally, we expect this study to help elucidate the lower limit of detection of this
technique.
7.3 MMS Spectroscopy
Preliminary results examining Multi-modal spectroscopy of breast tissue are very
promising. However, a more rigorous understanding of the relationship between a given
data parameter and tissue morphology is necessary. Microscopy studies, similar to those
used to develop the Raman spectral model, may provide a basis for understanding the
fluorescence and reflectance signals obtained from tissue. This study will be performed in
the pathology suite as breast tissue cannot be frozen for this experiment. Freezing the
tissue will change the fluorescence characteristics of the tissue. Also, in order to
successfully combine the optical modalities, a clear understanding of the probe volume
and sampling depth is necessary. Monte Carlo simulations will be performed to simulate
breast tissue and estimate sampling depth for breast tissue.
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7.4 Transdermal Needle
Optical techniques are less invasive than current diagnostic procedures. Our initial results
from in vivo and ex vivo Raman studies illustrate the potential for spectroscopic
transdermal needle measurements to provide breast cancer diagnosis and treatment. Due
to the fact that the Raman technique was shown to be applicable in a prospective study,
we will first build a Raman transdermal needle. A DRS/IFS transdermal needle will be
developed in the near future.
Transdermal needle measurements can be performed with either a front-viewing or a
side-viewing optical fiber probe. A front-viewing probe can be used in conjunction with a
vacuum-assisted biopsy procedure, discussed previously. Studies must be undertaken to
investigate whether the vacuum device and overall setup can be used in conjunction with
the probe.
A side-viewing probe can also be used for transdermal needle measurements. Our
laboratory has developed a side-viewing probe prototype based on a design that replaces
the sapphire ball lens with a half-ball lens backed by a mirror. The lens and mirror are
configured at a 450 angle, providing collection capabilities similar to the front-viewing
probe. The performance of the side-viewing probe is currently under investigation. This
type of probe can be used in conjunction with either a spring-deployed or a vacuum-
assisted biopsy needle. At the same time, a side-viewing probe will necessitate a method
for registering the tissue examined spectroscopically, which will lie somewhere in the
middle of the biopsy sample, with that examined by the pathologist. A side-viewing
probe is ultimately preferable to a front-viewing probe in terms of spectroscopic
advantage as it collects data from a larger tissue volume.
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Chapter 8. Conclusions
The overall goal of this thesis was to develop a multi-modal spectroscopic algorithm that
can be used to diagnose breast cancer. This process included the development of a
diagnostic algorithm based on diffuse reflectance and intrinsic fluorescence, and the
validation of a previously-developed algorithm for Raman spectroscopy. Each of these
steps has been addressed and results have been presented throughout this thesis.
The DRS/IFS algorithm is developed based on results obtained in a clinical pilot study.
This diagnostic algorithm incorporates four different pathologies and results in a high
sensitivity and specificity of 100 percent and 95.8 percent, respectively, and an overall
accuracy of 87.6 percent. MCR analysis proves that even without perfect initial guess
spectra we can achieve good fits and reasonable values for concentration of the intrinsic
fluorescence spectra's components. Investigation of different excitation wavelengths
reveals that there is limited need for all ten wavelengths currently employed by the
FastEEM instrument. In fact, the diagnostic algorithm is based solely on DRS parameters
obtained from white light excitation and IFS parameters obtained from 340 nm
excitation. In comparison, Palmer et al. [Palmer, 2003] also examined fluorescence and
DRS: the sensitivity and specificity in discriminating malignant and nonmalignant tissues
were 70 and 92 percent, respectively; at the same time sensitivity (30 percent) and
specificity (78 percent) of DRS along was significantly lower; combination of two
techniques did not improve the classification accuracy. This finding will help in the
development of our next generation FastEEM instrument as well as for a new instrument
that combines the Raman and DRS/IFS modalities.
The Raman spectroscopy algorithm is applied in a prospective manner and shown to be
an effective diagnostic tool. The sensitivity and specificity of the validated algorithm is
88.9 percent and 90.6 percent, respectively, with an overall accuracy of 81 percent.
A multi-modal diagnostic technique is developed and preliminary results are very
promising. It is clear that by combining Raman and DRS/IFS modalities we are able to
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increase our sensitivity, specificity, and overall accuracy to 100 percent, 97.9 percent,
and 92.4 percent, respectively. A new MMS instrument will be developed and tested in
future clinical studies.
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